This site is intended for Healthcare Professionals outside the U.S.

It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

In adult patients with Ph+ CML-CP

The journey toward critical milestones starts with
TASIGNA® (nilotinib) capsules

An image illustrating the importance of achieving EMR.
An image illustrating how many patients achieved MR4.5 with TASIGNA.
An image illustrating the percentage of patients treated with TASIGNA that did not progress to advanced phase or blast crisis.
An image explaining how many patients switched to TASIGNA from imatinib.
An image illustrating how many patients remained in TFR following discontinuation of TASIGNA.
An image illustrating the 10-year data with TASIGNA.
An image illustrating that TASIGNA will help navigate the CML journey.
CML Diagnosis

EMR, early molecular response; MR, molecular response; AP, accelerated phase; BC, blast crisis; TFR, treatment-free remission.

Line Break

References: 1. Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014;123(9):1353-1360.  2. Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30(3):232-238.  3. Habucky K, Duverger B, Kreft R, Kozlovsky V. TASIGNA® (nilotinib) 50 mg, 150 mg and 200 mg hard capsules core data sheet, version 1.8. West Sussex, United Kingdom: Novartis Europharm Limited; 2016:1-54. 4. Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044-1054.

This is an international website for TASIGNA® (nilotinib) and is intended for healthcare professionals outside the U.S.
If you are a U.S. resident, please click here or on the U.S. Residents link on this page.